Risk assessment: Seasonal influenza 2013–2014 in the EU/EEA countries
This document is a routine and planned risk assessment of the 2013-2014 seasonal influenza in EU/EEA countries. Active circulation of influenza has started late in Europe in the 2013-2014 season, with a different timing across EU/EEA countries, states the annual ECDC risk assessment on seasonal influenza.
Risk assessment: Seasonal influenza 2014–2015 in the EU/EEA countries
This risk assessment covers the 2014–2015 influenza season in the European Union and European Economic Area (EU/EEA).
Risk assessment: Seasonal influenza 2012/13 in Europe (EU/EEA countries)
ECDC has produced an annual risk assessment of the seasonal influenza epidemics in Europe since the 2010/11 season following the model developed by ECDC during the 2009 pandemic. It gives an early description of the influenza season in the countries affected earliest, providing guidance and information to countries that are affected later, as influenza progresses across Europe over several months. It describes any specifics of the season, particularly in areas where public health or clinical actions are envisaged, as well as highlights areas of uncertainty where further work is required.
Risk assessment update: seasonal influenza, EU/EEA, 2016–2017
This updated risk assessment provides an overview of the current influenza situation in Europe.
Expert opinion on priority risk groups for influenza vaccination
This paper identifies and describes population groups at increased risk for severe outcomes of influenza (“risk groups”) and advocates vaccination for two major groups, namely a) persons in the older age group, usually 65 years and older; and b) persons with chronic medical conditions.
Expert opinion on neuraminidase inhibitors for the prevention and treatment of influenza - review of recent systematic reviews and meta-analyses
This ECDC expert opinion confirms earlier assessments by ECDC and national authorities that there is no significant new evidence to support any changes to the approved indications and recommended use of neuraminidase inhibitors (NAIs) in EU/EEA Member States.
Mid-season risk assessment: Seasonal influenza 2015–2016 in the EU/EEA countries
This risk assessment summarises the development of the 2015–16 influenza season, which so far has been characterised by a prevalence of type A viruses.
Expert Opinion on neuraminidase inhibitors for prevention and treatment of influenza (Feb 2016)
A consultation with European and international public health experts was convened to review data presented in newly conducted systematic reviews and meta-analyses regarding influenza antivirals, in order to develop an ECDC Expert Opinion.
ECDC Forward look risk assessment (Update 28 October 2010): Likely scenarios and uncertainties in the 2010/2011 influenza season in Europe and beyond
Likely scenarios and uncertainties in the 2010/2011 influenza season in Europe and beyond.
ECDC Forward Look Risk Assessment: Seasonal influenza 2010–2011 in Europe
The 2010/11 seasonal influenza epidemics in Europe are dominated so far by the A(H1N1)2009 viruses which emerged in the 2009 pandemic, although these are now considered seasonal viruses. This is an interim risk assessment and will be up-dated at intervals as more data and analyses emerge.